Discovery of 3g as an Orally Bioavailable, TIR Domain Selective, and Potent MyD88 Inhibitor for the Treatment of Acute Lung Injury
Journal of Medicinal Chemistry · 25.09.2025 · 68 (18) · 19626-19644
DOI: 10.1021/acs.jmedchem.5c01786 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 12.09.2025. Verfasst von Pan Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, China. Hauptthemen laut MEDLINE: Myeloid Differentiation Factor 88, Acute Lung Injury, Drug Discovery, Anti-Inflammatory Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Myeloid differentiation factor 88 (MyD88) plays a pivotal role in the inflammatory response. However, the number of MyD88 inhibitors is limited, and the effectiveness of current inhibitors is constrained, hindering the progress of clinical research. Herein, thirty-nine novel MyD88 inhibitors were developed based on our previously discovered lead compound c17, and the potent compound 3g was identified using ELISA and DSF assays. Compound 3g specifically and selectively targets the TIR domain of MyD88 rather than its DD domain, thereby preventing MyD88 self-polymerization and interaction with TLRs, which suppresses the activation of MAPK and NF-κB pathways. 3g exhibits a bioavailability of 63% and shows no substantial in vivo toxicity, maintaining notable stability in plasma and digestive juices. Moreover, 3g demonstrated significant anti-inflammatory efficacy and effectively mitigated ALI symptoms in CLP and LPS-induced ALI models. These data indicate that 3g possesses considerable potential as a MyD88 inhibitor for the treatment of ALI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, China.
- Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
- Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325001, China.
- College of Pharmacy, Chonnam National University, Gwangju 61186, South Korea.
- Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, China.
ORCID-Profile: Zhiwei Zheng, Guang Liang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, P., Dong, K., Zhu, L., Huang, N., Zhang, K., Lv, Y., Jiang, M., Chen, Q., Zou, Y., Chen, Z., Guo, M., Zheng, Z., Sun, C., Cho, Y. C., Liang, G., & Tang, Q. (2025). Discovery of 3g as an Orally Bioavailable, TIR Domain Selective, and Potent MyD88 Inhibitor for the Treatment of Acute Lung Injury. Journal of Medicinal Chemistry, 68(18), 19626-19644. https://doi.org/10.1021/acs.jmedchem.5c01786
Vancouver
Chen P, Dong K, Zhu L, Huang N, Zhang K, Lv Y, et al. Discovery of 3g as an Orally Bioavailable, TIR Domain Selective, and Potent MyD88 Inhibitor for the Treatment of Acute Lung Injury. Journal of Medicinal Chemistry. 2025;68(18):19626-19644. doi:10.1021/acs.jmedchem.5c01786
BibTeX
@article{Chen2025,
author = {Chen, Pan and Dong, Ke and Zhu, Luxiao and Huang, Nan and Zhang, Kaixin and Lv, Yuehua and Jiang, Miao and Chen, Qi and Zou, Yu and Chen, Zhichao and Guo, Mi and Zheng, Zhiwei and Sun, Chenhui and Cho, Young-Chang and Liang, Guang and Tang, Qidong},
title = {Discovery of 3g as an Orally Bioavailable, TIR Domain Selective, and Potent MyD88 Inhibitor for the Treatment of Acute Lung Injury},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {18},
pages = {19626--19644},
doi = {10.1021/acs.jmedchem.5c01786}
}
EUVIMED